<DOC>
	<DOCNO>NCT01969136</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy 2 fixed dos EVP-6124 compare placebo 26 week subject mild moderate Alzheimer 's disease currently receive stable treatment previously treat acetylcholinesterase inhibitor .</brief_summary>
	<brief_title>Study Safety Effectiveness Two Doses Investigational Study Drug EVP-6124 Subjects With Alzheimer 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Cholinesterase Inhibitors</mesh_term>
	<criteria>Ages ≥55 ≤85 year Informed consent form ( ICF ) sign subject legally acceptable representative studyspecific procedure subject perform ICF sign support person/caregiver studyspecific procedure support person/caregiver perform Clinical diagnosis dementia due probable AD consistent criterion establish workgroup National Institute Aging Alzheimer 's Disease Association Clinical decline within 12 month screen onset symptom least 12 month longer screen , may include documented cognition , functional , objective assessment clinical judgment investigator subject 's refer physician subject experience clinical decline within last 12 month Magnetic resonance imaging ( MRI ) compute tomography ( CT ) scan perform within 12 month screen , finding consistent diagnosis dementia due AD without clinically significant comorbid pathology . If MRI CT scan unavailable occur great 12 month screen , assessment complete finding confirm subject enters runin period ( Day 14 ) ( copy report available study site ) MiniMental State Examination ( MMSE ) score ≥14 ≤24 screening confirm Day 1 prior randomization ( fluctuation ±2 point acceptable Day 1/baseline ) Clinical Dementia Rating Global score ( CDRGS ) ≥1 ( least mild dementia ) screening confirm Day 1 prior randomization Modified Hachinski Ischemic Scale ( mHIS ) score ≤4 screen Fertile , sexually active subject ( men woman ) must use effective method contraception study . Female subject female partner male subject must surgically sterile ( hysterectomy bilateral tubal ligation ) , postmenopausal least 1year , willing practice adequate method contraception childbearing potential ( defined consistent use combine effective method contraception [ include least 1 barrier method ] ) Reliable capable support person/caregiver , live household , interacts subject approximately 4 time per week available attend clinic visit person possible Subject living home , senior residential setting , institutional set without need continuous ( ie , 24hour ) nursing care General health status acceptable participation 26week study Fluency ( oral write ) language standardized test administer Receiving stable dose acetylcholinesterase inhibitor ( AChEI ) ( donepezil , rivastigmine galantamine ) least 3 month ( 90 day ) screen continuous dose least 6 month OR presently receive AChEI ( least 30 day screen ) , history previous AChEI treatment ( subject receive donepezil 23 mg currently within 3 month screen ineligible ) Exposure experimental drug , experimental biologic experimental medical device within 2 month ( 60 day ) screen Prior participation amyloid vaccination clinical study time past completion passive amyloid vaccination study within 6 month screen Inability swallow tablet In judgment investigator , inability subject support person/caregiver complete 26week study Inability ≥75 % compliant singleblind study drug Inability adequately cooperate complete cognitive testing procedure study assessment Residence skilled nursing facility Untreated vitamin B12 folate deficiency ( treat , must stably treat least 6 month screen ) Clinically significant ( judgment investigator ) abnormal serum electrolyte ( sodium , potassium , magnesium ) repeat test Clinically significant untreated hypothyroidism ( treat , thyroidstimulating hormone level thyroid supplementation dose must stable least 6 month screen ) Insufficiently control diabetes mellitus ( judgment investigator ) require insulin Renal insufficiency ( serum creatinine &gt; 2.0 mg/dL ) Malignant tumor within 3 year screen ( except squamous basal cell carcinoma cervical carcinoma situ localize prostate cancer ) Female subject pregnant , nursing , plan become pregnant study Unstable medical condition clinically significant judgment investigator Alanine transaminase ( ALT ) aspartate transaminase ( AST ) &gt; 2.5 time upper limit normal History myocardial infarction unstable angina within 6 month screen History 1 myocardial infarction within 5 year screen Clinically significant ( judgment investigator ) cardiac arrhythmia ( include atrial fibrillation ) , cardiomyopathy , cardiac conduction defect ( subject pacemaker acceptable ) Symptomatic hypotension hypertension ( supine diastolic blood pressure &gt; 95 mmHg ) ( judgment investigator ) Clinically significant abnormality screen baseline electrocardiogram ( ECG ) , include necessarily limit confirm correct QT interval ( QTc ) value ≥450 msec male ≥470 msec female . In subject QRS value &gt; 120msec , QTc value &lt; 500 msec may eligible follow discussion Medical Monitor . Stroke within 18 month screen , history stroke concomitant onset dementia History brain tumor , subdural hematoma , clinically significant ( judgment investigator ) spaceoccupying lesion CT MRI Head trauma clinically significant ( judgment investigator ) loss consciousness within 12 month screen concurrent onset dementia Onset dementia secondary ( judgment investigator ) cardiac arrest , surgery general anesthesia , resuscitation Specific degenerative central nervous system ( CNS ) disease diagnosis AD ( eg , Huntington 's disease , CreutzfeldJacob disease , Down 's syndrome , FrontoTemporal Dementia , Parkinson 's disease ) Subjects history prior treatment AChEI ( donepezil , rivastigmine , galantamine ) Memantine currently within 30 day screen Antipsychotics ; low dos ( judgment investigator , except clozapine ) allow give sleep disturbance , agitation and/or aggression , subject receive stable dose least 3 month screen ( within 8 hour cognitive test ) Tricyclic antidepressant monoamine oxidase inhibitor ; antidepressant allow subject receive stable dose least 3 month screen Antiepileptic medication take control seizures Chronic intake opioidcontaining analgesic Sedating H1 antihistamine Nicotine therapy ( include patch ) , varenicline ( Chantix ) , similar therapeutic agent within 30 day screen Clinically significant urine drug screen serum alcohol test result judgment investigator History ischemic colitis ischemic enterocolitis</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Alzheimer 's disease</keyword>
	<keyword>Cognition</keyword>
	<keyword>Alpha-7 nAChR</keyword>
</DOC>